FDA Clears Roche’s Enspryng for Thyroid Eye Disease, Introducing Home-Based Injection Option

The U.S. Food and Drug Administration has granted approval to Roche’s Enspryng, also known as satralizumab, for adults living with thyroid eye disease. With this decision, patients may receive the medicine through an injection under the skin at home, either independently or with help from a trained caregiver.

A New Direction for TED Care

Thyroid eye disease is an immune-driven disorder linked to thyroid dysfunction. It can lead to inflamed and swollen eye tissues, bulging eyes, discomfort, double vision and, in more serious cases, vision loss. Roche estimates that roughly 155 individuals in every 100,000 are affected by the condition.

Enspryng works by blocking interleukin-6 receptor signalling, a pathway involved in inflammation. The medicine is a humanised monoclonal antibody designed to bind both soluble and cell-surface forms of the IL-6 receptor.

The regulatory decision follows a priority review by the FDA. It also broadens the use of satralizumab in the United States, where the therapy was first cleared in 2020 for neuromyelitis optica spectrum disorder.

Evidence Behind the Decision

Roche’s filing was supported by two Phase III studies, SatraGO-1 and SatraGO-2. Together, the trials included 258 adults from 19 countries, with participants assigned equally to receive either satralizumab or a placebo.

SatraGO-1 did not achieve its primary effectiveness goal at week 24. However, SatraGO-2 delivered positive outcomes among participants with active thyroid eye disease.

At week 24, 52.9 percent of patients treated with Enspryng showed a response in eye protrusion, compared with 23.4 percent of those given placebo. For double vision, 60.7 percent of Enspryng recipients achieved a reduction, against 25.8 percent in the placebo group.

Roche said the findings in the overall SatraGO-2 study population, which included both active and chronic disease, were aligned with the results seen in patients with active TED. The company also stated that no unexpected safety concerns emerged and that the observed safety pattern matched what has already been established for satralizumab in NMOSD.

Why the Approval Matters

Many current treatments for thyroid eye disease depend on intravenous infusion, which can require repeated clinic visits and add to the day-to-day burden for patients. A self-administered or caregiver-administered subcutaneous option may offer a more convenient maintenance approach.

Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said the approval introduces an important treatment choice for people who have had limited options for managing the disease.

The FDA clearance gives Enspryng a second approved use in the United States. It also places Roche in a stronger position within the thyroid eye disease market, where ease of administration may become an important differentiator alongside clinical outcomes and safety.

Roche continues to evaluate satralizumab in other immune-related neurological conditions. In September, the FDA accepted the company’s application for MOG antibody-associated disease under priority review, with an agency decision anticipated in January 2027.